FBIO and FBIOP Related Headlines
Go Back- Fortress Biotech to Participate in A.G.P.’s Annual Virtual Healthcare Conference
- Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
- Fortress Biotech unit to sell rare disease voucher for $205 million
- UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
- Fortress Biotech unit begins phase 3 dotinurad gout trials
- Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics’ Global Phase 3 Trials of Dotinurad for the Treatment of Gout
- Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $205 Million Series A Financing
- Fortress Biotech to Present at the H.C. Wainwright 27th Annual Global Investment Conference
- Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
FBIO and FBIOP Related Press Releases
Go Back- Fortress Biotech to Participate in A.G.P.’s Annual Virtual Healthcare Conference
- Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
- UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
- Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics’ Global Phase 3 Trials of Dotinurad for the Treatment of Gout
- Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $205 Million Series A Financing
- Fortress Biotech to Present at the H.C. Wainwright 27th Annual Global Investment Conference
- Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
